Phlow Announces Close of $37M Series C Financing to Accelerate Modern Medicine Development and Manufacturing in AmericaRichmond, VA, July 22, 2025 (GLOBE NEWSWIRE) -- Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced the successful close of its Series C financing round at an increased valuation from previous funding. The $37 million raise supports the Company’s mission of helping brilliant minds bring medicines to life through advanced development and manufacturing in America. The growing Company’s Series C round was led by Align Private Capital LLC, a woman-owned investment firm which manages private family office direct investment vehicles, and was supported by additional new and follow-on investors.
Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in AmericaRichmond, Virginia, April 22, 2025 (GLOBE NEWSWIRE) -- Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced today a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure. Marking a period of exceptional growth and momentum, Phlow has more than doubled in size and now employs over 90+ highly skilled scientists and professionals dedicated to building a resilient, high-quality pharmaceutical supply chain on U.S. Soil.
Phlow Corp. Achieves Key Milestone Toward Full Epinephrine Production — Made in AmericaValidation Completed for a Novel, Cost-Competitive Epinephrine Active Pharmaceutical Ingredient Process, Drug Master File Successfully Filed
Phlow Corp. Appoints General Gustave F. Perna to the Phlow Business Advisory BoardRichmond, VA, May 06, 2024 (GLOBE NEWSWIRE) -- Phlow Corp., a U.S.-based certified B Corporation leveraging advanced development and manufacturing processes to re-imagine the domestic production of pharmaceutical products critical to U.S. healthcare, announced today that it has appointed General Gustave F. Perna to the Phlow Business Advisory Board (PBAB). As America's modern medicine manufacturer, Phlow works closely with its business advisory board, a team made up of internationally recognized leaders and visionaries, to drive a strategy focused on stabilizing our supply chain and ending chronic shortages of essential medicines and medical countermeasures for Americans.
Phlow Earns B Corp Certification Continuing Its Commitment to Improve Quality, Reliability, and Access to Essential MedicationsRichmond, VA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Phlow Corp., a Public Benefit Corporation, today announced that it has joined a select group of purpose-driven businesses by becoming the first pharmaceutical manufacturer based in America to earn B Corporation™ (B Corp™) certification. The new certification further emphasizes Phlow’s commitment to improving access and availability of domestically produced, high-quality pharmaceuticals and active pharmaceutical ingredients through advanced manufacturing and environmentally-friendly manufacturing processes.
Phlow Announces the Appointment of Kerry Ingalls and Guy Villax to its Board of Directors.Richmond, Virginia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Phlow Corp., a Public Benefit pharmaceutical manufacturer, announced today the appointment of Kerry Ingalls and Guy Villax to its Board of Directors amid a period of rapid growth and operational scale-up of facilities for Phlow. Ingalls and Villax will join Phlow's board, made up of internationally recognized pharmaceutical, biotech, and healthcare leaders, on a mission to re-shore the supply of the Nation's most essential medicines.
Phlow Included in BARDA Contract Development and Manufacturing Organization Network to Provide Domestic API Capability for Essential Medicines and Medical Countermeasures
Phlow Corp., a U.S.-based essential medicines impact company, today announced that it has been approved for inclusion in the Biomedical Advanced Research and Development Authority (BARDA) contract development and manufacturing organization (CDMO) network. The network is part of a comprehensive effort by the U.S. government to provide a domestically integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools to address public health emergencies.
Statement of Phlow Corp. on the Introduction of the “PREPARE Act”
Today Phlow Corp. released the following statement on the introduction of S.2740, the Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines (PREPARE) Act of 2021 in the United States Senate.
Phlow Corp. Receives The U.S Department of Health and Human Services, Office of Small and Disadvantaged Business Utilization, Small Business Prime Contractor of the Year Award
The U.S. Department of Health and Human Services (HHS), recently announced that Phlow Corp. has been awarded the Office of Small and Disadvantaged Business Utilization (OSDBU), Small Business Prime Contractor of the Year Award. Phlow Corp. is a U.S.-based, public benefit corporation committed to solving America’s broken essential medicine supply chain. This award recognizes Phlow for its performance during the previous fiscal year on its contract with HHS.
